Georgios D. Panos

Prof. Dr. Georgios D. Panos

Eye Department, Queen's Medical Center, Nottingham University Hospitals, Nottingham, UK
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in Journal of International Medical Research
Verified
Journal Article
Open access
AJAhmed Javed
Ahmed Javed
AKAishwarya Khanna
Aishwarya Khanna
EPEleanor Palmer
Eleanor Palmer
CWCraig Wilde
Craig Wilde
AZAnwar Zaman
Anwar Zaman
Georgios D. PanosGeorgios D. Panos
Georgios D. Panos
This narrative review presents a comprehensive examination of optical coherence tomography angiography (OCTA), a non-invasive retinal vascular imaging technology, as reported in the existing literature. Building on the coherence tomography principles of standard OCT, OCTA further delineates the retinal vascular system, thus offering an advanced alternative to conventional dye-based imaging. OCTA provides high-resolution visualisation of both the superficial and deep capillary networks, an achievement previously unattainable. However, image quality may be compromised by factors such as motion artefacts or media opacities, potentially limiting the utility of OCTA in certain patient cohorts. Despite these limitations, OCTA has various potential clinical applications in managing retinal and choroidal vascular diseases. Still, given its considerable cost implications relative to current modalities, further research is warranted to justify its broader application in clinical practice.

1 September 2023 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
Georgios D. PanosGeorgios D. Panos
Georgios D. Panos
ALArun Lakshmanan
Arun Lakshmanan
PDPanagiotis Dadoukis
Panagiotis Dadoukis
Matteo Ripa, MD, PhD, FEBO, FEBOS-CRMatteo Ripa, MD, PhD, FEBO, FEBOS-CR
Matteo Ripa, MD, PhD, FEBO, FEBOS-CR
LMLorenzo Motta
Lorenzo Motta
WAWinfried M Amoaku
Winfried M Amoaku
Degenerative eye conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are major contributors to significant vision loss in developed nations. The primary therapeutic approach for managing complications linked to these diseases involves the intravitreal delivery of anti-vascular endothelial growth factor (VEGF) treatments. Faricimab is a novel, humanised, bispecific antibody that simultaneously binds all VEGF-A isoforms and Angiopoietin-2, which has been approved by regulatory agencies, such as the US Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA), for the treatment of neovascular AMD and diabetic macular oedema (DMO). Intravitreal faricimab holds the promise of reducing the treatment burden for patients with these conditions by achieving comparable or superior therapeutic outcomes with fewer clinic visits. The scope of faricimab’s application includes addressing complex macular conditions such as DMO. This review intends to elucidate the distinctive pharmacological characteristics of faricimab and provide an overview of the key clinical trials and real-world studies that assess its effectiveness and safety in treating degenerative macular diseases.

1 September 2019 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
HMHorace Massa
Horace Massa
SPSpyros Y Pipis
Spyros Y Pipis
TATemilade Adewoyin
Temilade Adewoyin
AVAthanasios Vergados
Athanasios Vergados
SPSudeshna Patra
Sudeshna Patra
Georgios D. PanosGeorgios D. Panos
Georgios D. Panos
Macular edema (ME) is the most common sight-threatening complication in uveitis. The diagnostic and therapeutic management of the uveitic macular edema (UME) might be challenging due to the complex diagnostic workup and the difficulties physicians face to find the underlying cause, and due to its usually recurrent nature and the fact that it can be refractory to conventional treatment. Some of the mild cases can be treated with topical steroids, which can be combined with non-steroid anti-inflammatory drugs. However, immunomodulators such as methotrexate, tacrolimus, azathioprine, cyclosporine and mycophenolate mofetil together with anti-tumor necrosis factor-α (anti-TNF alpha) monoclonal antibodies such as adalimumab and infliximab, may be required to control the inflammation and the associated ME in refractory cases, or when an underlying disease is present. This review of the literature will focus mostly on the non-infectious UME.

1 January 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
SFStefan Futterknecht
Stefan Futterknecht
Eleftherios ChatzimichailEleftherios Chatzimichail
Eleftherios Chatzimichail
KGKonstantin Gugleta
Konstantin Gugleta
Georgios D. PanosGeorgios D. Panos
Georgios D. Panos
ZGZisis Gatzioufas
Zisis Gatzioufas
The cornea, as the outermost layer of the eye, plays a crucial role in vision by focusing light onto the retina. Various diseases and injuries can compromise its clarity, leading to impaired vision. This review aims to provide a thorough overview of the pharmacological properties, therapeutic potential and associated risks of Rho-associated protein kinase (ROCK) inhibitors in the management of corneal diseases. The article focuses on four key ROCK inhibitors: Y-27632, fasudil, ripasudil, and netarsudil, providing a comparative examination. Studies supporting the use of ROCK inhibitors highlight their efficacy across diverse corneal conditions. In Fuchs’ endothelial corneal dystrophy, studies on the application of Y-27632, ripasudil, and netarsudil demonstrated noteworthy enhancements in corneal clarity, endothelial cell density, and visual acuity. In pseudophakic bullous keratopathy, the injection of Y-27632 together with cultured corneal endothelial cells into the anterior chamber lead to enhanced corneal endothelial cell density and improved visual acuity. Animal models simulating chemical injury to the cornea showed a reduction of neovascularization and epithelial defects after application of fasudil and in a case of iridocorneal endothelial syndrome netarsudil improved corneal edema. Addressing safety considerations, netarsudil and ripasudil, both clinically approved, exhibit adverse events such as conjunctival hyperemia, conjunctival hemorrhage, cornea verticillata, conjunctivitis, and blepharitis. Monitoring patients during treatment becomes crucial to balancing the potential therapeutic benefits with these associated risks. In conclusion, ROCK inhibitors, particularly netarsudil and ripasudil, offer promise in managing corneal diseases. The comparative analysis of their pharmacological properties and studies supporting their efficacy underscore their potential therapeutic significance. However, ongoing research is paramount to comprehensively understand their safety profiles and long-term outcomes in diverse corneal conditions, guiding their optimal application in clinical practice.

3 July 2023 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
Georgios D. PanosGeorgios D. Panos
Georgios D. Panos
FBFrank Boeckler
Frank Boeckler
Statistical Analysis in Clinical and Experimental Medical Research: Simplified Guidance for Authors and Reviewers

1 June 2016 in Journal of Refractive Surgery
Verified
Journal Article
Closed access
ZGZisis Gkatzioufas
Zisis Gkatzioufas
FRFrederik Raiskup
Frederik Raiskup
DODavid O'BRart
David O'BRart
ESEberhard Spoerl
Eberhard Spoerl
Georgios D. PanosGeorgios D. Panos
Georgios D. Panos
Farhad HafeziFarhad Hafezi
Farhad Hafezi
PURPOSE: To assess the efficacy of a modified high concentration riboflavin solution containing benzalkonium chloride 0.01% for transepithelial corneal cross-linking (CXL). METHODS: In this prospective, interventional multicenter cohort study, 26 eyes of 26 patients with documented progressive keratoconus who underwent transepithelial CXL were included. Follow-up at 6 and 12 months postoperatively included slit-lamp examination, uncorrected and corrected distance visual acuity (logMAR), maximum keratometry (Kmax), and corneal pachymetry (corneal thinnest point) as determined by Scheimpflug imaging. Statistical analysis was performed using repeated measures analysis of variance and the Friedman test for parametric and non-parametric data, respectively. P values less than .05 were considered significant. RESULTS: Kmax did not change significantly at postoperative months 6 and 12. Changes in corneal thinnest point did not change postoperatively over 12 months. Uncorrected and corrected distance visual acuity did not change postoperatively. Progression (defined by an increase in Kmax greater than 1.00 diopter occurred in 46% of eyes at 12 months. Corneal epithelial defects were observed in 46% of the patients and marked punctate corneal epitheliopathy/loose epithelium in 23% of the patients in the immediate postoperative period. No corneal infection, sterile infiltrates, or haze were observed. CONCLUSIONS: Transepithelial CXL with an enhanced riboflavin solution did not effectively halt progression of keratoconus. Significant epithelium damage was evident in the immediate postoperative period. [ J Refract Surg. 2016;32(6):372–377.]